Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1614 1621 1629 1691
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | Non-Final OA | Novartis AG |
| 18281674 | METHODS AND MATERIALS FOR TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 19296888 | PYRANOPYRIDINE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
| 18280111 | THREE-COORDINATE AU(I) PROBES AND USE IN SELECTIVELY DISRUPTING MITOCHONDRIA IN CANCER CELLS | Non-Final OA | University of Kentucky Research Foundation |
| 18019972 | Pharmaceuticals for Treating or Preventing Nidoviruses and Picornaviruses | Final Rejection | The University of Chicago |
| 18558211 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Duke University |
| 18568375 | COSMETIC PRODUCT CONSISTING OF PACKAGING AND A PREPARATION CONTAINING PROPYLENE GLYCOL DIESTER | Non-Final OA | BEIERSDORF AG |
| 18006129 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18262628 | OPHTHALMIC PREPARATION ADMINISTERED BY EYE DROPS AND USED FOR PREVENTING AND TREATING DRY MACULAR DEGENERATION AND RETINAL LIGHT DAMAGE | Non-Final OA | CHENGDU RUIMU BIOPHARMACEUTICALS CO., LTD. |
| 18572109 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR PARKINSON'S DISEASE | Non-Final OA | Kyowa Pharma Chemical Co., Ltd. |
| 18571942 | GRANULATE COMPOSITION COMPRISING NILOTINIB | Non-Final OA | HELM AG |
| 18568368 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Non-Final OA | Epizyme, Inc. |
| 18561529 | Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain | Non-Final OA | Sorrento Therapeutics, Inc. |
| 18496122 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | Final Rejection | ReveraGen BioPharma, Inc. |
| 18558163 | ANTIBACTERIAL COMPOUND | Non-Final OA | DISCUVA LIMITED |
| 18553596 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Non-Final OA | HEPTARES THERAPEUTICS LIMITED |
| 18282672 | COMPOSITIONS AND METHODS FOR MANAGING NEPHROPATHY | Non-Final OA | SAMI-SABINSA GROUP LIMITED |
| 18282572 | CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD | Non-Final OA | KINKI UNIVERSITY |
| 18282007 | Long Acting Injectable Compositions of Cariprazine or its Pharmaceutically Acceptable Salts | Non-Final OA | Cipla Limited |
| 18446558 | USE OF ADENOSINE A2B RECEPTOR AS TARGET IN DRUGS FOR PREVENTION AND/OR TREATMENT OF PRURITUS | Non-Final OA | The Fourth Affiliated Hospital, ZJU |
| 18360533 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | Non-Final OA | Noema Pharma AG |
| 18260778 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | Non-Final OA | BTG INTERNATIONAL INC. |
| 18256198 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST | Non-Final OA | ARTELO BIOSCIENCES LIMITED |
| 18029529 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF INFLAMMATION | Non-Final OA | REVEN PHARMACEUTICALS INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy